Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

FDA Allows Unapproved Drugs To Stay On the Market

Posted by Jane Akre
Tuesday, October 27, 2009 11:21 AM EST
Category: Major Medical
Tags: FDA, Drugs, Cancer, AIDS, HIV, GAP Drug Approval

The FDA has failed to follow up on a number of fast-tracked medications with questionable value that are still on the market.


IMAGE SOURCE: Wikimedia Commons/ tablets/ author: Ragesoss

Unapproved Yet Generating Profits

A report released Monday by the Government Accountability Office (GAO) finds many drugs currently on the market and being used by patients have not had postmarket surveillance completed for safety and efficacy.

That despite 2007 legislation passed by Congress giving the Food and Drug Administration (FDA) greater leverage over drug makers to complete their studies.

Since 1992, 90 of the drugs in the report have been essentially fast-tracked to get to patients with life-threatening illnesses such as H.I.V, AIDS, and cancer. Patients can use drugs under this approval even though they have not been tested for long-term benefit, such as an extended life.

The catch is that the drugs are eventually supposed to go through postmarket studies to confirm they are safe so they can stay on the market. The critical GAO report says studies have been completed for only two-thirds of the drugs and none have been pulled from the market.

The GAO says in a statement the FDA has the authority to expedite the withdrawal of a drug off the market if a study is not completed or if it fails to confirm a drug’s benefit, but it “has never exercised its authority, even when such study requirements have gone unfulfilled for nearly 13 years.”

The FDA’s response is that some of the drugs are the only ones on the market for the condition they treat and a blanket process won’t work.

"Millions of patients with serious or life-threatening illnesses have had earlier access to new safe and effective treatments," thanks to the program, the FDA said in its response to the report.

Of the 90 drugs, 15 have uncompleted studies for more than five years, while several have been lingering for more than eight years, among them:

  • A drug such as ProAmatine (Shire Laboratories) for low blood pressure has gone unreviewed for more than 13 years. During that time it has generated more than $257 million in sales, reports CBS.

  • Iressa (AstraZeneca) for lung cancer was approved by the FDA in 2003 after it was found to reduce the size of the tumor. Later studies found it did not extend life. Meanwhile hundreds of reports have come in of a sometimes fatal pneumonia. AZ says Iressa is not available to new patients.

"FDA has fallen far short of where it should be for patient safety," said Sen. Charles Grassley, R-Iowa, who requested the investigation.

Sidney Wolf, MD with the consumer group Public Citizen says the FDA policy is sending a message to companies that the agency has no teeth.

"The FDA has talked a lot about doing more enforcement, but this is an area where they're basically defending not enforcing the law,” he says.

The GAO says the FDA needs to clarify when it will revoke an approval to push along the review process. #

1 Comment

Posted by Marianne Skolek
Tuesday, October 27, 2009 11:49 AM EST

Message to the FDA -- please send a message to Purdue Pharma, maker of OxyContin, that this country has had enough in deaths and addictions of their blockbuster drug, OxyContin. We have a modern day Holocaust because of the free reign Purdue Pharma was given in criminally marketing OxyContin. Enough already -- put some muscle into your punch FDA -- and hit Purdue Pharma where it hurts -- in their wallets!

Marianne Skolek
National Activist for Victims of OxyContin and
Purdue Pharma - a criminally convicted pharmaceutical company

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes